Brief: Zealand Pharma And OTR Therapeutics Enters Multi-Program Strategic Collaboration
11/12/2025 11:48
Dec 11 (Reuters) - Zealand Pharma A/S ZELA.CO: ZEALAND PHARMA AND OTR THERAPEUTICS ENTER MULTI-PROGRAM STRATEGIC COLLABORATION AND LICENSE AGREEMENT TO DEVELOP NOVEL THERAPEUTICS FOR METABOLIC DISEASES Source text: ID:nGNX4KwBs7 Further company coverage: ZELA.CO ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)